ArticleFrontiers in endocrinology2026
Safety, short-term patient-reported outcomes, and cosmetic satisfaction of gasless transaxillary endoscopic thyroidectomy: a retrospective analysis of 530 patients.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gasless transaxillary endoscopic thyroidectomy (GTET) eliminates visible cervical scarring and has been increasingly adopted for managing unilateral thyroid diseases. This study aimed to evaluate its safety, feasibility, perioperative complications, procedure-specific discomfort, and cosmetic satisfaction. Methods: We retrospectively reviewed 530 consecutive patients with unilateral thyroid disease who underwent GTET between January 2023 and February 2026. To evaluate surgical experience, 406 patients with papillary thyroid carcinoma (PTC) were chronologically divided into early- and late-phase groups (203 cases each). Multivariable linear regression adjusted for baseline confounders. Serum PTH and calcium were measured at 36 hours. Chest wall sensory disturbance and sternocleidomastoid (SCM) discomfort were evaluated at 1 week and 3 months using a modified Verbal Rating Scale (VRS, 0-3), and cosmetic satisfaction via Patient Satisfaction Score (PSS, 0-3). Results: Among 530 patients (406 PTC, 124 benign), four (0.75%) required conversion to open surgery (two for internal jugular vein bleeding, two for intraoperative recurrent laryngeal nerve transection with immediate neurorrhaphy; none developed permanent paralysis). Postoperative hematoma occurred in six patients (1.13%; one reoperated, five managed conservatively). Two tracheal and one esophageal injury were repaired endoscopically, all recovering within 2 months. Transient vocal cord paralysis occurred in 34 patients (6.42%), permanent in three (0.57%), and transient hypoparathyroidism in 11 (2.08%). Multivariable regression confirmed the late phase independently predicted shorter operative time (β = -14.2 min, P < 0.001) and higher postoperative PTH (β = 4.8 pg/mL, P < 0.001). Chest wall disturbance and SCM discomfort improved significantly from 1 week to 3 months (VRS: 1.41 ± 0.53 vs. 0.36 ± 0.42 and 1.84 ± 0.55 vs. 0.43 ± 0.53, P < 0.001). Over a median follow-up of 25.3 months (IQR: 9.2-34.6), no primary site recurrences occurred. Six patients (1.13%) developed metachronous micro-PTC (0.1-0.4 cm) in the contralateral lobe, successfully treated with completion thyroidectomy. Conclusions: GTET is a safe and feasible option for carefully selected patients with unilateral thyroid disease, offering favorable cosmetic satisfaction and acceptable morbidity. Procedure-related symptoms are transient. Accumulating surgical experience independently improves operational efficiency and parathyroid preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.